Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
December 23, 2010

AstraZeneca and Abbott Pull NDA for Lipidemia Drug

  • AstraZeneca and Abbott are ceasing development of the FDA-filed mixed lipidemia therapy candidate Certriad™. The drug is a combination of AstraZeneca’s Crestor (rosuvastatin calcium) and Abbott’s Trilipix (fenofibric acid).

    The firms had filed an NDA with FDA for Certriad in June 2009. In March received a complete response letter (CRL) from the agency.

    They say the joint decision to drop the drug follows a careful review of the CRL and the resulting regulatory delay, which led them to conclude that development of Certriad is no longer commercially viable.

Related content

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.